The sell-side consensus price target has fallen below the share price for the first time ($26.61 vs $26.82), a sign of capitulation

Key points

• A psychological turning point: the shares closed at $26.82 on 12 Jun (-7.1%), and the average Wall Street target of $26.61 is now below the share price. Analysts as a group have moved from 'how much upside is left' to 'there is no upside left'. Over one year the target went from $44.16 to $24.15 in March and $26.61 on 12 Jun, broadly tracking the share price with little independent judgement.
• Ratings from 17 analysts: 1 Buy, 3 Overweight, 12 Hold, 1 Underweight, 0 Sell. Classic fence-sitting, with no strong conviction either way. The averages differ by source: TIKR's is $26.61 and MarketBeat's consensus is $28.70, because they draw on different analyst pools. But the direction is the same: targets keep coming down.
• The split between narrative and fundamentals is now visible. Over the past two weeks, news flow (a new CMO who is a peptide specialist, the Novo partnership rumour, the $20 billion peptide TAM) repeatedly pushed the shares up, while sell-side earnings and valuation expectations worsened at the same time (on 11 Jun Zacks recorded this quarter's consensus EPS being cut by 125.7% within 30 days). A target below the share price means the stock has lost the support of sell-side backing.
• Q1 review: revenue was $608.1 million (+4% year on year, 1.4% below the $616.8 million consensus). GAAP EPS was a loss of $0.40 against an expected profit of $0.03, a double miss. But management frames it as a 'deliberate choice': in March it stopped advertising compounded weight-loss drugs and shifted to branded GLP-1, triggering about $33 million in restructuring charges (about $28 million of which cut gross margin by 5 percentage points). Excluding these, gross margin was 70% (65% reported).
• Cash flow is solid: operating cash flow of $89 million and free cash flow of $53 million, with full-year guidance raised to $2.8 billion to $3 billion. The margin damage is engineered, not a sign of falling demand. This is the core of the bull-bear split: bears think branded GLP-1 economics are structurally thinner, while bulls see short-term noise.
• Follow-ups: as of this morning, the 8-K with the results of the 11 Jun annual shareholder meeting was still not on EDGAR (the latest filing is still from 2 Jun). Results of the CEO pay vote and Kofi's board nomination are yet to be disclosed. The 23 Jul window for the FDA to clear peptides for 503A compounding is approaching.